• Meropenem in Resistance Research Workflows

  2026-09-28

  Use Meropenem as a defined β-lactam comparator in susceptibility testing and Gram-negative infection models—not as a shortcut for predicting activity against resistant isolates. This guide connects careful assay design with recent Enterobacter cloacae resistance surveillance and practical troubleshooting.

• Neomycin sulfate for RNA, DNA, and Channel Studies

  2026-09-27

  Neomycin sulfate is a mechanistic probe for nucleic-acid structure and ryanodine receptor channel experiments—not simply an antimicrobial. This workflow-focused guide shows how to build controlled pilot assays and interpret them alongside allergic-rhinitis microbiome research without implying the compound was tested in that study.

• EGFR/HER2 Inhibition in Translational Oncology

  2026-09-26

  A translational perspective on using BMS 599626 dihydrochloride to interrogate EGFR/HER2 signaling, connect pathway measurements to tumor phenotypes, and distinguish established evidence from emerging senescence questions.

• ATG4B Links Energy Deficiency to AML DNA Repair

  2026-09-25

  The study identifies a route by which energy deficiency can compromise genome maintenance: ATG4B moves into the nucleus, binds PRMT1, and reduces PRMT1-dependent MRE11 methylation. In AML models, ATG4B inhibition strengthened DNA damage responses and was associated with lower mutation burden and longer survival, making the pathway a mechanistic lead rather than an established treatment strategy.

• eIF4F, AKT1 and EZH2 Blockade in Resistant Melanoma

  2026-09-25

  In BRAFV600E A375 melanoma models, eIF4F inhibition with RocA triggered time-dependent ERK1/2–EZH2 and AKT1–eIF4E responses associated with reduced treatment sensitivity. The study reports that combining eIF4F, AKT1, and EZH2 inhibition improved anticancer effects in vitro and in vivo, offering a mechanistic rationale for testing multi-pathway strategies while leaving questions about dose, model breadth, and clinical translation open.

• Etoposide (VP-16): DNA Damage Research Guide

  2026-09-24

  Etoposide (VP-16) is a DNA topoisomerase II inhibitor used to study DNA damage and apoptosis in cancer models. Product-listed potency varies substantially by assay and cell line, so reported IC50 values should be treated as model-specific benchmarks rather than universal dose recommendations.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-09-24

  The study links elevated miR-18a with suppression of ALOXE3, connecting altered lipid metabolism to reduced ferroptotic sensitivity and increased glioblastoma cell migration. Its findings position the miR-18a/ALOXE3 axis as a mechanistic research target, while highlighting that ferroptosis and apoptosis are distinct outcomes that require separate experimental interpretation.

• Tau Ser356, Alzheimer’s Pathology, and NUAK Inhibition

  2026-09-23

  Taylor et al. report that tau phosphorylated at serine 356 (p-tau Ser356) increases with Alzheimer’s disease neuropathological stage and is commonly found in neurofibrillary tangles, with array tomography also showing its localization near synapses. Their slice-culture experiments show that WZ4003 lowers p-tau Ser356 in live human brain tissue, while mouse slices show broader changes in tau and neuronal and synaptic proteins—an important difference for interpreting NUAK-inhibitor studies.

• Linagliptin and the p-Tau Ser356 Translation Gap

  2026-09-23

  A translational framework for interpreting p-tau Ser356 biology, designing human brain slice experiments, and evaluating Linagliptin (BI-1356) without overstating evidence from a NUAK inhibitor study.

• ApexPrep DNA Plasmid Miniprep Kit Workflow

  2026-09-22

  Build reproducible plasmid workflows for cloning, sequencing, and AML gene-regulation studies with one alkaline-lysis platform. The ApexPrep DNA Plasmid Miniprep Kit combines support for high- and low-copy vectors with a practical troubleshooting framework for obtaining molecular biology grade plasmid DNA.

• Ruxolitinib: From JAK Inhibition to Immune Profiling

  2026-09-22

  Ruxolitinib (INCB018424) is more than a potent JAK1/2 inhibitor: its experimental value depends on matching pathway, progenitor, and immune readouts to the biological question. This guide connects quantitative pharmacology with high-dimensional immune profiling and explains how to design more interpretable combination studies.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-21

  Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that substantially improves detection of TOR pathway inhibitors compared with a wild-type strain background. The study also shows that canagliflozin produced no detectable TOR-dependent growth phenotype in this assay, illustrating how pathway-focused screening can distinguish metabolic research tools from candidate mTOR inhibitors.

• Ferrostatin-1 (Fer-1) in Ferroptosis Assays

  2026-09-21

  Ferrostatin-1 (Fer-1) provides a selective rescue control for distinguishing lipid peroxidation-driven cell death from nonspecific toxicity. This practical guide applies Fer-1 to erastin and butyrate workflows, 3D lung cancer stem-cell assays, and neurodegenerative disease models while emphasizing dose selection, orthogonal readouts, and troubleshooting.

• SARS-CoV-2 N Protein Rewires GADD34 Immunity

  2026-09-20

  Liu et al. identify an atypical stress-granule mechanism in which SARS-CoV-2 nucleocapsid protein recruits GADD34 mRNA into N/G3BP1-positive foci, weakening IRF3-dependent interferon signaling. The work connects RNA localization, stress-granule biology, and viral immune evasion while suggesting experimental strategies for dissecting RNA–protein interactions.

• Bestatin Chemistry Dissects Jasmonate Signaling

  2026-09-19

  The reference study established bestatin as a chemical genetics probe that activates COI1-dependent jasmonate responses while remaining partly uncoupled from jasmonic acid biosynthesis. By combining transcriptional profiling, developmental assays, and bestatin-resistant Arabidopsis mutants, the authors identified a practical route to discovering previously unrecognized regulators of plant hormone signaling.

8637 records 1/576 page Next 12345 下5页 Last page